Skip to Main Content

A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors

Conditions

Anus | Bones and Joints | Brain and Nervous System | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Other Hematopoietic | Phase I | Pediatrics | Unknown Sites | Breast | Cervix | Urinary Bladder

Phase 1a/1b

What is the purpose of this trial?

The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts (A and B). Participants will only enroll in one part.

  • Trial with
    Eli Lilly and Company
  • Start Date
    08/05/2019
  • End Date
    11/30/2020
Trial Image

For more information about this study, contact:

Nicole Sinclair

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/08/2019
  • Study HIC
    #2000024397